Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors
Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors
The purpose of this study is to determine whether the study drug, BMS-986142, is safe and effective in treating moderate to severe rheumatoid arthritis in subjects with an inadequate response to methotrexate or methotrexate and up to 2 tumour necrosis factor (TNF) Inhibitors. Patients who qualify will be randomized to either one of 3 doses of BMS-986142 or placebo in 1:1:1 randomization for 12 weeks. Disease activity and safety will be assessed over the course of the study.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Capital Federal, Buenos Aires 1015, Argentina
Capital Federal, Buenos Aires, Argentina
Kitakyushu-shi, Fukuoka 8078555, Japan
Kato-shi, HyĹŤgo 6731462, Japan
Sagamihara-shi, Kanagawa 2520392, Japan
Sasebo-shi, Nagasaki 8571195, Japan
Iruma-gun, Saitama 3500495, Japan
Kawagoe-shi, Saitama 3508550, Japan
Chuo-ku, Tokyo 1048560, Japan
Itabashi-ku, Tokyo 1738610, Japan
Meguro-ku, Tokyo 1538515, Japan
Shinjuku-Ku, Tokyo 1608582, Japan
Osaki-shi, 9896183, Japan
Mexico City, Distrito Fededral 11850, Mexico
Distrito Federal, 03100, Mexico
Santiago Compostela, 15702, Spain